|
CL2007002499A1
(es)
|
2006-08-30 |
2008-03-14 |
Phenomix Corp |
Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
|
|
JP5523831B2
(ja)
*
|
2006-08-30 |
2014-06-18 |
セルジーン コーポレイション |
５−置換イソインドリン化合物
|
|
US8877780B2
(en)
*
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
MX361467B
(es)
*
|
2008-10-29 |
2018-12-06 |
Celgene Corp |
Compuestos de isoindolina para uso en el tratamiento de cancer.
|
|
WO2012135299A1
(en)
|
2011-03-28 |
2012-10-04 |
Deuteria Pharmaceuticals Inc |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
|
US9290475B2
(en)
|
2013-03-14 |
2016-03-22 |
Deuterx, Llc |
3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
|
UA117141C2
(uk)
|
2013-10-08 |
2018-06-25 |
Селджин Корпорейшн |
Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
BR112016012795A2
(pt)
|
2013-12-06 |
2017-08-08 |
Celgene Corp |
Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6778114B2
(ja)
*
|
2014-04-14 |
2020-10-28 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
イミド系タンパク質分解モジュレーター及び関連する使用方法
|
|
US9499514B2
(en)
*
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2016057503A1
(en)
*
|
2014-10-07 |
2016-04-14 |
Celgene Corporation |
Use of biomarkers for predicting clinical sensitivity to cancer treatment
|
|
WO2016105518A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
MX390189B
(es)
|
2015-01-20 |
2025-03-20 |
Arvinas Operations Inc |
COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs.
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
BR112018013761A2
(pt)
*
|
2016-01-08 |
2018-12-11 |
Celgene Corp |
compostos antiproliferativos e suas composições farmacêuticas e usos
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
AU2017246453A1
(en)
*
|
2016-04-06 |
2018-11-08 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
|
ES2989988T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros heterorocíclicos para la degradación de proteínas diana
|
|
IL318681A
(en)
|
2016-10-11 |
2025-03-01 |
Arvinas Operations Inc |
Compounds and methods for targeted reduction of androgen receptor
|
|
AU2017367872B2
(en)
|
2016-11-01 |
2022-03-31 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
|
CN118834201A
(zh)
|
2016-12-01 |
2024-10-25 |
阿尔维纳斯运营股份有限公司 |
作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
KR102839545B1
(ko)
|
2016-12-23 |
2025-07-29 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CA3049912A1
(en)
|
2017-01-26 |
2018-08-02 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
JP2020506922A
(ja)
|
2017-01-31 |
2020-03-05 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CN112312904B
(zh)
|
2018-04-16 |
2025-01-07 |
C4医药公司 |
螺环化合物
|
|
SG11202009237XA
(en)
|
2018-04-23 |
2020-10-29 |
Celgene Corp |
Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
WO2020064002A1
(zh)
|
2018-09-30 |
2020-04-02 |
中国科学院上海药物研究所 |
异吲哚啉类化合物、其制备方法、药物组合物及用途
|
|
AU2019381688A1
(en)
*
|
2018-11-13 |
2021-06-03 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
CN111285850B
(zh)
|
2018-12-06 |
2022-04-22 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020181232A1
(en)
|
2019-03-06 |
2020-09-10 |
C4 Therapeutics, Inc. |
Heterocyclic compounds for medical treatment
|
|
KR20210152515A
(ko)
|
2019-04-12 |
2021-12-15 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
US11306101B2
(en)
|
2019-05-31 |
2022-04-19 |
Celgene Corporation |
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
|
|
CN114867727B
(zh)
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
WO2021069705A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Monte Rosa Therapeutics |
Isoindolinone compounds
|
|
CN119019369A
(zh)
|
2019-10-17 |
2024-11-26 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
US20230065745A1
(en)
|
2019-11-27 |
2023-03-02 |
Captor Therapeutics S.A. |
Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof
|
|
AU2020392427B2
(en)
|
2019-11-27 |
2024-03-07 |
Captor Therapeutics S.A. |
Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
|
|
PE20221582A1
(es)
|
2019-12-19 |
2022-10-06 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida de receptor de androgenos
|
|
TW202208345A
(zh)
|
2020-05-09 |
2022-03-01 |
美商亞文納營運公司 |
雙官能性化合物的製造方法、該雙官能性化合物的超純形式、及含彼之劑型
|
|
WO2022029138A1
(en)
|
2020-08-03 |
2022-02-10 |
Captor Therapeutics S.A. |
Low molecular weight protein degraders and their applications
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
KR20230069144A
(ko)
|
2020-09-14 |
2023-05-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
|
|
PE20230847A1
(es)
|
2020-09-23 |
2023-05-23 |
St Jude Childrens Res Hospital Inc |
Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon
|
|
WO2022146151A1
(en)
|
2020-12-30 |
2022-07-07 |
Captor Therapeutics S.A. |
Novel compounds which bind to cereblon, and methods of use thereof
|
|
MX2023008296A
(es)
|
2021-01-13 |
2023-09-29 |
Monte Rosa Therapeutics Inc |
Compuestos de isoindolinona.
|
|
EP4313047A1
(en)
*
|
2021-03-22 |
2024-02-07 |
Monte Rosa Therapeutics, Inc. |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
WO2022255889A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
EP4431505A4
(en)
*
|
2021-11-09 |
2025-09-24 |
Korea Res Inst Chemical Tech |
ISOINDOLINONE DERIVATIVE HAVING A GLUTARIMIDE MOTHER NUCLEUS AND ITS USE
|
|
EP4536656A1
(en)
|
2022-06-06 |
2025-04-16 |
C4 Therapeutics, Inc. |
Bicyclic-substituted glutarimide cereblon binders
|
|
US20260014133A1
(en)
*
|
2022-07-15 |
2026-01-15 |
St. Jude's Chidren's Research Hospital, Inc. |
SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
KR20240066904A
(ko)
*
|
2022-11-08 |
2024-05-16 |
주식회사 온코드바이오 |
아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
|
|
AU2024212035A1
(en)
|
2023-01-26 |
2025-08-14 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|
|
WO2024167423A1
(en)
|
2023-02-07 |
2024-08-15 |
Captor Therapeutics S.A. |
Gspt1 degrader compounds
|
|
KR102570883B1
(ko)
*
|
2023-04-13 |
2023-08-29 |
(주) 사이러스테라퓨틱스 |
신규한 gspt1 분해제 및 이의 용도
|
|
US12496301B2
(en)
|
2023-12-08 |
2025-12-16 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|